Author(s)

Witold Ryan

Affiliation(s)

Faculty of Pharmacy, Jagiellonian University Medical College, Medyczna 9, 30-688, Krakow, Poland. 

Corresponding Author

Witold Ryan

ABSTRACT

Fentanyl-like substances are a class of synthetically powerful anesthetics represented by fentanyl. In recent years, the abuse and trafficking situation has been severe in many countries around the world, posing a great threat to people's health and social stability. By reviewing the abuse, pharmacological and toxicological effects, detection methods and control conditions of fentanyl-like substances, we can improve people's understanding of their basic properties, research status and control conditions, and provide reference for future research.

KEYWORDS

Fentanyl; Fentanyl-like substances; Drug abuse; Pharmacological and toxicological effects; Detection methods; Drug control

CITE THIS PAPER

Witold Ryan. Research progress on fentanyl-like substances. Journal of Pharmaceutical and Medical Research. 2024, 6(1): 6-12. DOI: 10.61784/jpmr240123.

REFERENCES

[1] Chu YL. The expansion situation and prevention and control strategy offentanyl substance abuse. J Beijing Police College, 2019(3): 109-115.

[2] Yang LH. Reflection on the management of the whole class of fentanyl substances in China. J Yunnan Police Officer Academy, 2019(4): 1-4.

[3] Liu ZM. Abuse and control offentanyl and its derivatives: hazards and challenges. Chin J Drug Depend, 2017, 26(4): 274-276.

[4] UNODC. Fentanyl and its anolognes-50 year on. Global SMART Update, 2017, 17: 3-8.

[5] Karila L, Marillier M, Chaumette B. New synthetic opioids: part of a new addiction landscape. Neurosci Biobehav Rev, 2019, 106: 133-140.

[6] Baumann MH, Pasternak GW. Novel synthetic opioids and overdose deaths: tip of the iceberg? Neuropsychopharmacology, 2018, 43(1): 216-217.

[7] UNODC. Understanding the global opioid crisis. Global SMART Update, 2019, 21: 6-9.

[8] Burns SM, Cunningham CW, Mercer SL. DARK classics in chemical neuroscience: fentanyl. ACS Chem Neurosci, 2018, 9(10): 2428-2437.

[9] Comer SD, Cahill CM. Fentanyl: receptor pharmacology, abuse potential, and implications for treatment. Neurosci Biobehav Rev, 2019, 106: 49-57.

[10] Xiao JZ. Pharmacology and clinical practice of remifentanil. J Med Theor Pract, 2009, 22(2): 158-160.

[11] Yang S, Xu Q. Research progress in the fentanyl and its derivatives in the treatment of cancer pain. Shanghai Med Pharm J, 2015(5): 32-36.

[12] Pacifici GM. Clinical pharmacology of fentanyl in preterm infants. A review. Pediatr Neonatol, 2015, 56(3): 143-148.

[13] Schaefer CP, Tome ME, Davis TP. The opioid epidemic: a central role for the blood brain barrier in opioid analgesia and abuse. Fluids Barriers CNS, 2017, 14(1): 32.

[14] Ninkovi? J,Roy SRole of the mu-opioid receptor in opioid modulation of immune function. Amino Acids,2013,45(1): 9-2

[15] Xu L, Li YH. Studies on pharmacological action and clinical application of sufentanil. Anhui Med Pharm J, 2011(3): 375-377.

[16] Xiao GF, Lv H. Observation on the analgesic effect and stress state of brachial plexus block combined with remifentanil during replantation of severed fingers. J Logist Univ PAPF , 2018, 27(6): 48-51.

[17] Ma L, Wang XL. Evaluation of sufentanil in intravenous postoperative analgesia and clinical anesthesia. Gen J Stomat, 2018, 5(32): 191-192.

[18] Dumas EO, Pollack GM. Opioid tolerance development: a pharmacokinetic/pharmacodynamic perspective. AAPS J, 2008, 10(4): 537-551.

[19] Sutou I, Nakatani T, Hashimoto T. Fentanyl tolerance in the treatment of cancer pain: a case of successful opioid switching from fentanyl to oxycodone at a reduced equivalent dose . J Pain Palliat Care Pharmacother, 2015, 29(2): 161-165.

[20] Neunhoeffer F, Hanser A, Esslinger M. Ketamine infusion as a counter measure for opioid tolerance in mechanically ventilated children: a pilot study. Paediatr Drugs, 2017, 19(3): 259-265.

[21] Volkow ND, Jones EB, Einstein EB. Prevention and treatment of opioid misuse and addiction: a review. JAMA Psychiatry, 2019, 76(2): 208-216.

[22] Hao W, Zhao M, Li J. Addication medicine: theory and practice. Beijing: People's Medical Publishing House, 2016: 14-71.

[23] Aceto M. Dependence studies of new compounds in the rhesus monkey, rat and mouse. Problems Drug Dependence , 1996, 1998: 338.

[24] Pan LS, Cui YY, Ren YH. Dependence -producing potential of remifentanil. Chin J Drug Depend, 2002, 11(2): 107-110.

[25] Bekhit MH. Opioid-induced hyperalgesia and tolerance. Am J Ther, 2010, 17(5): 498-510.

[26] YueK, WenRJ. Neuroimmune mechanism of opiates addiction . J Jianghan Univ(Nat Sci Ed. ), 2017, 45(3): 241-246.

[27] Essawi MY. Fentanyl analogues with a modified propanamido group as potential affinity labels: synthesis and in vivo activity . Pharmazie, 1999, 54(4): 307-308.

[28] Lin H, Higgins P, Loh HH. Bidirectional effects offentanyl on dendritic spines and AMPA receptors depend upon the internalization of mu opioid receptors. Neuropsychopharmacology, 2009, 34(9): 2097-211.

[29] Wei X, Wei W. Role of gabapentin in preventing fentanyl-and morphine-withdrawal-induced hyperalgesia in rats. JAnesth, 2012, 26(2): 236-241.

[30] Dolinak D. Opioid toxicity. Acad Forensic Pathol, 2017, 7 (1): 19-35.

[31] Liu C, Kang Y. How to evaluate and select sedatives and analgesics considering their cardiovascular and respiratory effects？ Chin J Crit Care Intensive Care Med Electron Ed, 2017, 3(4): 291-295.

[32] Liu XB, Xu GP. Research progress of mechanism about remifentanil slowing down heart rate. Med Recap, 2012, 18(23): 4027-4029.

[33] Chen L, Zhao YH, Liu XL. Progress in the application of sufentanil in the treatment of cancer pain. Chin J Pain Med, 2018, 24(11): 65-68.

[34] Guo ZF. Clinical application of sufentanil. J Chengde Med Col, 2016, 33(6): 516-519.

[35] Qian ZH, Li P, Zheng H. Mass fragmentation characteristics offentanyl analogue. J Chin Mass Spectrom Soc, 2018, 39(5): 79-88.

[36] Gupta PK, Yadav SK, Bhutia YD. Synthesis and comparative bioefficacy of N-(1-phenethyl-4-piperidinyl)propionanilide(fentanyl)and its 1-substituted analogs in Swiss albino mice. Med Chem Res, 2013, 22(8): 3888-3896.

[37] Swaminathan SK, Fisher J, Kandimalla KK. Sensitive determination offentanyl in low-volume serum samples by LC-MS/MS . AAPS Pharmscitech, 2018, 19(7): 2812-2817.

[38] Mochizuki A, Nakazawa H, Adachi N. Identification and quantification of mepirapim and acetyl fentanylin authentic human whole blood and urine samples by GC-MS/MS and LC-MS/ MS. Forensic Toxicol, 2018, 36(1): 81-87.

[39] Misailidi N, Athanaselis S, Nikolaou P. A GC-MS method for the determination of furanylfentanyl and ocfentanil in whole blood with full validation. Forensic Toxicol, 2019, 37(1): 238-244.

[40] Liu CM. The application prospect of fourier transform infrared spectroscopy in narcotics control area. Spectrosc Spectral Anal, 2018, 38(S1): 400-401.

[41] Mallette JR, Casale JF, Toske SG. Characterization of (2R, 4S)-and(2R, 4R)-2-Methylfentanyland their differentiation from cis-and trans-3-methylfentanyl. Forensic Chem, 2018, 8: 64-71.

[42] Li KK, Miao CY, Wang DK. Detection of drugs by raman spectroscopy and data analysis based on R software. J Light Scat, 2018, 30(2): 156-162.

[43] Kong LC, Zuo GM, Liu GQ. Surface-enhanced raman spectroscopy for trace fentanyl detection in water. J Light Scat, 2010, 22(1): 34-38.

[44] Tiscione NB, Wegner K. Validation of the Neogen?Fentanyl ELISA kit for blood and urine. J Anal Toxicol, 2017, 41(4): 313-317.

[45] Smith JS, Mochel JP, Borts DJ. Adverse reactions to fentanyl transdermal patches in calves: a preliminary clinical and pharmacokinetic study. Vet Anaesth Analg, 2018, 45(4): 575-580.

[46] Wan HN. Application and development of immunoassay in drug testing and identification. J Liaoning Police Coll, 2018, 20(2): 65-69.

[47] Center For Medical Device Evaluation. NMPA. Notice of issuance of registered designated inspection notice on 30 August, 2019. (2019-08-30)[2019-09-12]. https: //www.cmde.org.cn/CL0151/19680.html.

[48] Zaknoun H, Binette MJ, Tam M. Analyzing fentanyland fentanyl analogues by ion mob spectrometry. Int J Ion Mobil Spectrom, 2019, 22(1): 1-10.

[49] UNODC. Recommended methods for the identification and analysis offentanyland its analogues in biological specimens: manual for use by national drug analysis laboratories. (2017-12-07).

[50] Zhang WY, Lin JF, Yan J. Rapid screening of fentanyl substances and their precursors without the standards. J Anal Sci, 2019, 35(5): 635-642.

[51] United States Drug Enforcement Administration. Schedules of controlled substances: temporary placement offentanyl-related substances in schedule I. (2018-02-06). https: //www.deadiversion.usdoj.gov/fed_regs/rules/2018/fr0206_4.htm.

[52] EMCDDA. Fentanils and synthetic cannabinoids: driving greater complexity into the drug situation-An update from the EU Early Warning System. (2018-06-01). http: //www.emcdda.europa.eu/publications/rapid-communications/fentanils-and-synthetic-cannabinoids-ews-updateen.

[53] Supreme people's court. Notice on the issuance of the catalogue of varieties of narcotic drugs and the catalogue of psychotropic drugs. (2019-11-11).

[54] China National Narcotic Control Commision. China conducts the management of four fentanyl substances such as carfentanil. (2017-02-16).